GGrantIndex
← Search

Cancer Epidemiology, Prevention & Control

$26,996P30FY2019CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

PROJECT SUMMARY - CANCER EPIDEMIOLOGY, PREVENTION AND CONTROL (CEPaC) The CEPaC program plays a central role in the scientific, clinical and public health mission of AECC, and is the focal point for the translation of laboratory-based research into studies at the population level. The broad aims of CEPaC are to conduct studies in human populations to determine the behavioral, environmental and molecular etiologic risk factors that underlie cancer development and outcomes, (especially actionable targets for screening, prevention, and treatment), and further, to implement interventions and test their effectiveness in the community. CEPaC has long been recognized for its contributions to the study of HPV and to molecular epidemiologic cancer research. However, in recent years, cancer prevention and control research has greatly expanded, with a strong focus on the largely poor and minority Bronx population. CEPaC is organized into four major themes: (i) Infectious Risk Factors, including oncogenic HPV, HIV, HCV, and the human microbiome; (ii) Hormonal, Obesity, and Inflammation-Related Risk Factors; (iii) Genetic/Epigenetic Risk Factors; and (iv) Cancer Prevention, Control, and Implementation Science, encompassing prevention, health care delivery, health disparities, survivorship and outcomes, especially in the local catchment area. CEPaC research has also been impactful on clinical guidelines and practice, and recent studies will maintain this trend. For example: (i) CEPaC laboratory advancements led to the characterization of HPV sub-lineages and HPV DNA methylation, both sufficiently associated with strong risk of cervical cancer and precancer with the potential to improve the positive predictive value (PPV) of recently FDA-approved ?primary HPV screening?; (ii) obese women with normal insulin levels were shown to have no greater risk of incident post-menopausal breast cancer than normal weight women with normal insulin, but those with elevated insulin had significantly increased risk regardless of obesity status ? results that demonstrate the importance of etiologic biomarkers in risk stratification (e.g., versus obesity), characterizing possible carcinogenic pathways, and as targets for chemoprevention; (iii) a novel signature of metastatic risk based on laboratory and animal model studies was strongly associated with metastasis of ER+/HER2- tumors in postmenopausal women, and may have a role in guiding treatment decisions; (iv) firefighters who worked at the 9/11 WTC disaster site were found to be at increased risk of developing MUGUS, a precursor of multiple myeloma, leading to changes in monitoring practices in this group. Finally, the recent Einstein/Montefiore merger has increased shared interest in collaborative cancer prevention initiatives in the Bronx, including community needs assessment, defining cancer-health priorities, community outreach, and studies of the impact of these initiatives. There are 30 program members from 14 departments. Current NCI funding is 7.7M (direct); total peer-reviewed funding is 10.9M (direct). There have been 811 publications since July 2013 of which 31% represent intra-programmatic, 14% inter-programmatic, and 62% represent collaborations with investigators at other institutions.

View original record on NIH RePORTER →